Nitroxoline induces cell apoptosis by inducing MDM2 degradation in small-cell lung cancer
Jin-Guo Yu1, Cheng-Hong Ji1, Min-Hua Shi1
1Department of Respiratory Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Abstract:
The proto-oncogene MDM2 is a nuclear-localized E3 ubiquitin ligase, which promotes tumor formation by targeting tumor suppressor proteins, such as p53, for proteasomal degradation. In this study, the anti-infective drug nitroxoline (NXQ) was screened out to effectively inhibit cell survival of small-cell lung cancer (SCLC) cells, and induce SCLC cell apoptosis by suppressing antiapoptotic proteins (such as Bcl-2 and MCL1) and upregulating proapoptotic protein Bim. In the mechanistic study, NXQ was found to downregulate MDM2 expression by inducing its proteasomal degradation, and thus upregulated p53 expression, which was a substrate protein of MDM2. Moreover, overexpression of MDM2 decreased the cytotoxicity of NXQ on SCLC cells. These results demonstrated that NXQ displayed anti-SCLC activity by suppressing MDM2 expression, which suggested that anti-infective NXQ had potential for SCLC treatment by targeting the MDM2/p53 axis.
Insights
The anti-infective drug nitroxoline (NXQ) inhibits small-cell lung cancer (SCLC) by targeting MDM2. This leads to increased p53 levels, promoting cancer cell death and suggesting NXQ as a potential SCLC therapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- MDM2 is a proto-oncogene and E3 ubiquitin ligase promoting tumor formation by degrading tumor suppressors like p53.
- Small-cell lung cancer (SCLC) is an aggressive form of lung cancer with limited treatment options.
Purpose of the Study:
- To investigate the anti-cancer effects of nitroxoline (NXQ) on SCLC cells.
- To elucidate the molecular mechanisms underlying NXQ's anti-SCLC activity, focusing on the MDM2/p53 pathway.
Main Methods:
- Screening of anti-infective drugs for SCLC cell survival inhibition.
- Analysis of apoptosis-related proteins (Bcl-2, MCL1, Bim) expression.
- Investigation of MDM2 and p53 expression and degradation following NXQ treatment.
- Assessment of MDM2 overexpression effects on NXQ cytotoxicity.
Main Results:
- Nitroxoline (NXQ) effectively inhibited SCLC cell survival and induced apoptosis.
- NXQ suppressed antiapoptotic proteins (Bcl-2, MCL1) and upregulated proapoptotic Bim.
- NXQ induced proteasomal degradation of MDM2, leading to increased p53 expression.
- Overexpression of MDM2 attenuated NXQ's cytotoxicity in SCLC cells.
Conclusions:
- NXQ exhibits anti-SCLC activity by downregulating MDM2 expression and subsequently upregulating p53.
- The MDM2/p53 axis is a key target for NXQ's anti-cancer effects in SCLC.
- Anti-infective NXQ shows potential as a therapeutic agent for SCLC treatment.
Related Concept Videos
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
Somatic...
Mechanisms of Retrovirus-induced Cancers
Induced-fit Model
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Proteins: From Genes to Degradation
Transcription is the synthesis of RNA...


